Researchers have designed a new DNA-based treatment that targets PCSK9, a protein closely tied to high LDL cholesterol and atherosclerosis. Their most effective molecule reduced PCSK9 protein by 87% in human liver cells and lowered cholesterol by 47% in genetically modified mice after a single injection.